Xponance Inc. Invests $33,000 in Nektar Therapeutics (NASDAQ:NKTR)

Xponance Inc. bought a new position in shares of Nektar Therapeutics (NASDAQ:NKTRGet Rating) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 10,171 shares of the biopharmaceutical company’s stock, valued at approximately $33,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. Vantage Consulting Group Inc acquired a new stake in Nektar Therapeutics during the second quarter worth approximately $41,000. Nisa Investment Advisors LLC raised its stake in Nektar Therapeutics by 964.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 12,141 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 11,000 shares in the last quarter. Mackenzie Financial Corp purchased a new stake in Nektar Therapeutics in the second quarter valued at $47,000. Verition Fund Management LLC acquired a new position in Nektar Therapeutics in the first quarter valued at $55,000. Finally, Corton Capital Inc. purchased a new position in shares of Nektar Therapeutics during the second quarter worth about $58,000. Hedge funds and other institutional investors own 92.30% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on Nektar Therapeutics in a report on Wednesday, October 12th. They issued a “hold” rating for the company. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, Nektar Therapeutics currently has an average rating of “Hold” and a consensus target price of $8.40.

Nektar Therapeutics Trading Up 2.5 %

Nektar Therapeutics stock opened at $2.42 on Wednesday. The stock has a 50 day moving average of $2.94 and a two-hundred day moving average of $3.54. Nektar Therapeutics has a twelve month low of $1.99 and a twelve month high of $12.76. The stock has a market capitalization of $454.85 million, a price-to-earnings ratio of -0.99 and a beta of 1.04.

Nektar Therapeutics (NASDAQ:NKTRGet Rating) last issued its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.23. The firm had revenue of $23.63 million during the quarter, compared to the consensus estimate of $23.31 million. Nektar Therapeutics had a negative return on equity of 81.70% and a negative net margin of 477.85%. Equities analysts predict that Nektar Therapeutics will post -2.14 earnings per share for the current year.

Insider Transactions at Nektar Therapeutics

In related news, CEO Howard W. Robin sold 38,014 shares of the stock in a transaction dated Wednesday, November 16th. The shares were sold at an average price of $3.57, for a total transaction of $135,709.98. Following the completion of the transaction, the chief executive officer now directly owns 979,793 shares of the company’s stock, valued at $3,497,861.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Howard W. Robin sold 38,014 shares of the company’s stock in a transaction on Wednesday, November 16th. The stock was sold at an average price of $3.57, for a total transaction of $135,709.98. Following the transaction, the chief executive officer now owns 979,793 shares of the company’s stock, valued at $3,497,861.01. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Jonathan Zalevsky sold 13,460 shares of the stock in a transaction dated Wednesday, November 16th. The shares were sold at an average price of $3.57, for a total transaction of $48,052.20. Following the completion of the transaction, the insider now owns 313,663 shares of the company’s stock, valued at approximately $1,119,776.91. The disclosure for this sale can be found here. In the last quarter, insiders sold 62,569 shares of company stock worth $223,371. Company insiders own 3.38% of the company’s stock.

About Nektar Therapeutics

(Get Rating)

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19.

Recommended Stories

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.